Horiba Showcases New Generation Automated Hemostasis Analyzers at ISTH 2022
Posted on 07 Jul 2022
Horiba Medical (Kyoto, Japan) showcased the latest additions to its Yumizen G range of hemostasis analyzers and reagents at ISTH 2022 Congress - the premier event in the field of thrombosis and hemostasis - at London’s Excel from 9-13 July 2022.
At ISTH 2022, HORIBA introduced its new generation Yumizen G800 and G1550 hemostasis analyzers, as well as new ready-to-use reagents for frequently undertaken blood coagulation tests. With these introductions, HORIBA now offers a complete portfolio of hemostasis systems and an innovative reagent range suitable for all laboratory sizes and requirements. HORIBA’s comprehensive Yumizen G hemostasis product range fully supports high quality and cost-effective screening and assessment of bleeding disorders. The new generation of HORIBA Yumizen G800 and G1550 automated analyzers are designed for managing the coagulation, thrombophilia diagnostics and monitoring requirements of clinical laboratories with mid- to high-workloads. Supporting coagulant nephelometry, immuno-turbidimetric and chromogenic testing, these analyzers offer independent and integrated measurement channels.
The new hemostasis line also includes: liquid reagents for more than 80% of laboratory activity; pre-calibrated tests; continuous sample access and loading; as well as innovative management of reflex and additional tests. For urgent samples, it also offers eight STAT sample positions available at any time. Yumizen G systems use only one cuvette per test to avoid waste and overconsumption. The Yumizen G range has been designed to optimize costs, reduce expenses and reduce impact on environment.
Alongside the Yumizen G hemostasis range, HORIBA presented a variety of new specialty reagent additions, including dRVVT, protein S, protein C and Antithrombin screening and confirmation. HORIBA demonstrated its HELO laboratory automation platforms for hematology. Based on the combination of innovative and proven technologies, the HELO solution is capable of enhancing productivity and efficiency of any type of laboratory. At ISTH 2022, HORIBA also hosted a symposium with key opinion leaders in hemostasis from the UK and France presenting on the latest reagent evaluations and advancements in thrombophilia diagnosis.
“Leveraging our many years of expertise in hematology, we have meticulously designed all our Yumizen G systems to ensure that they are easy-to-use, efficient, robust and safe, along with a continuously expanding repertoire of tests,” said Bruno Pougault, Global Hemostasis Product Manager, HORIBA Medical.
Related Links:
Horiba Medical
